A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 27 Mar 2017 Status changed from completed to discontinued.
    • 01 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Mar 2015 Planned End Date changed from 1 Dec 2016 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top